• Record: found
  • Abstract: found
  • Article: not found

The role of bcl-2 expression in breast carcinomas (Review).

Oncology Reports

Treatment Outcome, Breast, metabolism, Breast Neoplasms, mortality, pathology, therapy, Epithelial Cells, Female, Genes, bcl-2, Humans, Neoplasm Invasiveness, Prognosis, Proto-Oncogene Proteins c-bcl-2, biosynthesis, Survival Analysis

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      The proto-oncogene bcl-2 is demonstrated to block a final common pathway leading to apoptosis and is expressed in more than half of human breast cancers. Invasive breast cancer has reduced bcl-2 immunostaining compared with normal breast epithelia and preinvasive breast lesions. As an inhibitor of apoptosis, bcl-2 should correlate with highly aggressive tumor biology and resistance to hormonal/cytotoxic therapy. However, high bcl-2 expression has been shown to associate with a number of favorable prognostic factors including ER positivity, PgR positivity, low histological grade, well-differentiated tumor, absence of c-erbB-2 and p53. Unexpectedly, numerous studies have shown that tumors with high bcl-2 expression are more responsive to hormone therapy and have more favorable disease-free and overall survival. The clinical significance of bcl-2 in tumorigenesis and prognosis of breast carcinomas from the data recently published are reviewed. Its role in modulation of hormonal/cytotoxic therapy and future directions are also discussed.

      Related collections

      Author and article information



      Comment on this article